在患有1型糖尿病的青少年中,甘油三糖指数
Marta García-Poblet1, Ana Pilar Nso-Roca2, José Miguel Martínez-Sanz1
1Nursing department, Faculty of Health Science, University of Alicante 03692 Alicante, Spain; Research group on Applied Dietetics, Nutrition and Body Composition (DANuC), University of Alicante 03692 Alicante, Spain.
Diabetes research and clinical practice
|February 14, 2025
概括
甘油三糖 (TyG) 指数与1型糖尿病 (T1DM) 青少年的HbA1c相关. 这种简单的生物标志物可以帮助监测血糖控制,并识别代谢并发症的风险.
科学领域:
- 内分泌学 在内分泌学.
- 代谢障碍 代谢障碍 代谢障碍
- 儿科糖尿病 儿科糖尿病
背景情况:
- 在1型糖尿病 (T1DM) 中血糖控制对于预防长期并发症至关重要.
- 血红蛋白A1c (HbA1c) 检测虽然准确,但可能昂贵,限制了一些患者的可访问性.
- 三甘油-葡萄糖 (TyG) 指数显示,作为各种人群中胰岛素耐药性和血糖状况的指标,具有前途.
研究的目的:
- 研究1型糖尿病诊断的青少年中甘油三糖指数 (TyG) 和血糖控制之间的关联.
- 探索TyG指数的潜力,作为一个具有成本效益和可访问的标志物,用于监测儿科患者的T1DM.
主要方法:
- 进行了一项横截面研究,涉及36名患有T1DM的青少年 (50%为女性).
- 收集的数据包括社会人口统计,生长参数,血糖控制标志物 (包括HbA1c) 和血液测试结果.
- 根据临床和生化数据,分析了包括TyG,TyG-BMI和TyG腰围在内的各种指数.
主要成果:
- 在较高的TyG指数和增加的身体质量指数 (BMI) 参数 (百分位数和z-score) 之间观察到统计学上显著的正相关性.
- 提升的TyG指数与较高的甘油三,HbA1c和葡萄糖水平相关.
- 泰格指数还显示了与其他代谢指数的关联,包括甘油三/高血压,总胆固醇/高血压,泰格-BMI和泰格-腰围.
结论:
- 甘油三糖 (TyG) 指数是一种简单的,非侵入性的生物标志物,可以补充T1DM青少年的HbA1c监测.
- 泰格指数具有潜力作为一种查工具,用于早期检测代谢并发症,如胰岛素耐药性和脂质失调症,在这个人群中.
- 进一步的研究可以验证TyG指数在儿科T1DM管理中常规临床使用.
相关概念视频
Diabetes Mellitus: Overview and Type I Subtype
2.4K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.4K
Insulin: Dosing Regimen and Adverse Effects
139
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
139
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Diabetes: Symptoms, Diagnosis, and Complications
498
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
498
Hypoglycemia and Glucagon
149
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
149
Dipeptidyl Peptidase 4 Inhibitors
164
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
164


